Journal article icon

Journal article

Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.

Abstract:

OBJECTIVE: This study evaluates the efficacy of agomelatine, the first antidepressant that is an agonist at MT(1)/MT(2) receptors and an antagonist at 5-HT(2C) receptor, in the prevention of relapse of depression following successful response. METHOD: Patients with DSM-IV-TR major depressive disorder who responded to an 8- or 10-week course of agomelatine 25- or 50-mg daily treatment were randomly assigned to receive continuation treatment with agomelatine (n=165) or placebo (n=174) during a...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.4088/jcp.08m04548

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Psychiatry
Rouillon, F More by this author
Journal:
The Journal of clinical psychiatry
Volume:
70
Issue:
8
Pages:
1128-1137
Publication date:
2009-08-05
DOI:
EISSN:
1555-2101
ISSN:
0160-6689
URN:
uuid:4966a8a1-b950-4057-bd2b-73778acde552
Source identifiers:
97993
Local pid:
pubs:97993

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP